51. 全身性強皮症 Scleroderma Clinical trials / Disease details
臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100041982 | 2021-03-01 | 2021-01-10 | An Open-Label Clinical Study to Evaluate the 24-Week Efficacy and 52-Week Safety of Baricitinib in Patients with Early Diffuse Cutaneous Systemic Sclerosis | An Open-Label Clinical Study to Evaluate the 24-Week Efficacy and 52-Week Safety of Baricitinib in Patients with Early Diffuse Cutaneous Systemic Sclerosis | Systemic Sclerosis | A:baricitinib 4mg;B:baricitinib2mg;C:no intervention; | Huashan Hospital, Fudan University | NULL | Recruiting | 18 | 70 | Both | A:25;B:50;C:50; | China |